Teva confirms efficacy and safety of Ajovy for prevention of migraine
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
A significant proportion of healthcare professionals still tend to favor branded drugs
Total value of the supplies of FC will be US$ 2.773 million
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Subscribe To Our Newsletter & Stay Updated